Zimbabwe has turned down a substantial American health deal valued at $367m (£272m) over five years due to Washington's demand for sensitive information.
The decision was revealed after a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa believed the deal was "skewed".
An official spokesman later clarified that the US was demanding access to genetic material for scientific study and profit while was unwilling to share the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for more talks to reach a agreement suitable to all parties so the nation's critical HIV treatment initiative can be sustained.
Wider Context
This development comes after a comparable case in Kenya, where a high court suspended a related health funding agreement following concerns were raised about the security of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump argued its expenditure was "inefficient" and his administration was pursuing government-to-government deals to boost openness and accountability.
As per statements, 16 African countries have so far signed these new health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, with no equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Effectively, our country would provide the raw materials for scientific discovery with no assurance that the end products would be accessible to our people should a new pandemic emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were undermining structures already set up through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to manage future pandemics.
"This framework is designed to ensure that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," he added.
"We are open to ongoing discussions with our American counterparts on how subsequent co-operation might be designed in a way that respects the independence and dignity of both nations."
Medical Community Response
A leading public health body expressed it understood the government's concerns, but urged that talks must proceed since a large portion of the country's Aids initiatives relied on external financing.
"If specific concerns arise, such as those relating to information security or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," the group said.
The halted deal underscores the continuing debate between accepting crucial foreign assistance and safeguarding local interests in an increasingly data-driven world.